The project is based on many years of basic research regarding the analysis of the risk that tumor cells will form metastases. Directly analyzing this risk would provide invaluable information to healthcare staff on how aggressive tumor cells are. In cancer diagnoses, there is a fundamental problem that cell migration cannot be directly measured-. Cell migration is a prerequisite for metastasis and the fatal outcome of the disease.
In cancer diagnoses, there is a fundamental problem that cell migration cannot be directly measured-. Cell migration is a prerequisite for metastasis and the fatal outcome of the disease.
The research groups associated to Liv Diagnostics AB have been working to find new methods for cellular migration analysis. These efforts have resulted in a qualitative leap in technology that enables direct quantification of cell migration and, consequently, our product CellRACE can provide very important diagnostic information.
Greater accuracy in the assessment of whether a tumor will metastasize or not can play a decisive role in the choice of treatment strategy and CellRACE, therefore, has the potential to become a very valuable diagnostic tool in the oncology field.
- Our Basic Idea
The difference between our future and today's method
CellRACE differs from today's methods as it is based on quantification of cell migration, a physical property shared by all invasive tumors. With CellRACE you can measure tumor invasiveness and thus evaluate the risk of metastasis. If in a case of breast cancer, it is difficult to determine the risk of tumor migration, it is most likely that extensive treatment will be carried out, involving aggressive chemotherapy and surgical breast removal.
In cases where the diagnosis interprets a malignant tumor as benign, the patient risks a serious delay of the necessary treatment and the risk is that the tumor may form metastases, which may lead to a fatal outcome for the patient.
- The Product
The company's product is a diagnostic test that initially will be used for diagnosis and follow-up of breast cancer. However, the technology can potentially be used for other types of metastasizing cancers. A number of tests can be performed for each patient during the therapeutic phase of the disease.
This means that the CellRACE test should be used when biopsies are taken after the primary tumor has been detected. CellRACE is a 'lab-on-a-chip' product, which means that live cells from a biopsy can be analyzed. The information obtained is important in several different steps of the treatment process.